Rodrigo Botero SAS

Medellín, Antioquia 50030

1 studies enrolling now · 14 studies all time

What they study most

Atherosclerotic Cardiovascular Disease, Cardiovascular Disease, Covid-19, Diabetes Mellitus, Gastroparesis, Heart Failure, Hyperlipidemia, Obesity, Overweight, Rheumatoid Arthritis

Studies at this site

• Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity — Recruiting now
• A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With Heart Failure and Inflammation — Running, not enrolling
• Study to Evaluate the Efficacy (Effect on Disease) and Safety of Finerenone in Participants With Heart Failure and Left Ventricular Ejection Fraction (Proportion of Blood Expelled Per Heart Stroke) Greater or Equal to 40% — Completed
• Semaglutide Effects on Heart Disease and Stroke in Patients With Overweight or Obesity — Completed
• CPI-006 Plus Standard of Care Versus Placebo Plus Standard of Care in Mild to Moderately Symptomatic Hospitalized Covid-19 Patients — Stopped early
• A Safety and Efficacy Study of Relamorelin in Diabetic Gastroparesis Study 03 — Stopped early
• Diabetic Gastroparesis Study 05 — Stopped early
• A Safety and Efficacy Study of Relamorelin in Diabetic Gastroparesis Study 04 — Stopped early
• Study to Evaluate the Safety and Efficacy of Relamorelin in Participants With Diabetic Gastroparesis Study 02 — Stopped early
• A Pharmacokinetic/Pharmacodynamic Study Comparing PF-05280586 To Rituximab In Subjects With Active Rheumatoid Arthritis With An Inadequate Response To TNF Inhibitors (REFLECTIONS B328-01) — Completed
• The Evaluation of Bococizumab (PF-04950615; RN316) in Reducing the Occurrence of Major Cardiovascular Events in High Risk Subjects — Stopped early
• Rheumatoid Arthritis Extension Trial For Subjects Who Have Participated In Other PF-05280586 Trials (REFLECTIONS B328-04) — Completed
• Randomized Clinical Trial of Bococizumab (PF-04950615; RN316) in Subjects With Hyperlipidemia or Mixed Dyslipidemia at Risk of Cardiovascular Events — Completed
• The Evaluation of Bococizumab (PF-04950615;RN316) in Reducing the Occurrence of Major Cardiovascular Events in High Risk Subjects — Stopped early